The Glycaemic Benefits of a Very-low-carbohydrate Ketogenic Diet in Adults with Type 1 Diabetes Mellitus May Be Opposed by Increased Hypoglycaemia Risk and Dyslipidaemia
Understanding how these medications affect body composition, what clinical trials reveal about waist circumference changes, and how to maximize results through lifestyle modifications helps patients set realistic expectations for their weight management journey
Chief Medical Officer, Kailera Therapeutics: Oral ribupatide shows a potentially game-changing clinical profile Kailera Therapeutics plans to initiate another Phase 2 oral study this year Chief of Clinical Development, Metabolic Diseases, Hengrui Pharma confirmed plans to advance into Phase 3 in China 5 Oral + injectable = portfolio hedge Kaileras lead injectable ribupatide (KAI-9531) already showed: 19.2% mean weight loss at 36 weeks (Phase 3, China) Comparable to @Eli Lilly and Companys Zepbound Oral ribupatide now adds access, convenience, and lifecycle flexibility
'Every doctor's visit that I went to, she kept telling me, 'I really wish you would take this Ozempic',' Kelly said